Cas:1099597-81-5 (2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone manufacturer & supplier

Chemical Name:(2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone

CAS.NO:1099597-81-5

Synonyms:(2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone

Molecular Formula:C₁₁H₅Cl₂FN₂O

Molecular Weight:271.07500

HS Code:2933599090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:42.85000

Exact Mass:269.97600

LogP:3.15350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone Use and application,(2,6-dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone technical grade,usp/ep/jp grade.

Related News: J&J, in a statement, confirmed that the FDA authorized the two batches, but did not acknowledge the doses regulators decided should be tossed. (2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone manufacturer Roche’s second anti-tau antibody UCB0107, partnered with UCB, is also slated to enter deeper testing this year. Tau had appeared to have fresh promise as a rival of sorts to amyloid. Tau theory goes that neurofibrillary tangles that form inside cells clog up the brain, and clearing this can help Alzheimer’s patients. (2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone supplier The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. (2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone vendor The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. (2,6-Dichloropyrimidin-4-yl)-(4-fluorophenyl)methanone factory Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data.